非那雄胺
化学
睾酮(贴片)
二氢睾酮
还原酶
增生
杜他星
体内
前列腺癌
雄激素
酶
5α还原酶抑制剂
前列腺
药理学
内科学
生物化学
癌症
医学
激素
生物
生物技术
作者
Neelima Dhingra,Akansha Sharma,Priyanka Rana,Poonam Arora,Tanzeer Kaur
出处
期刊:Current Enzyme Inhibition
[Bentham Science]
日期:2022-05-27
卷期号:18 (3): 180-193
标识
DOI:10.2174/1573408018666220525123827
摘要
Background and Objective: Testosterone under the influence of 5α-reductase enzyme gets converted to dihydrotestosterone and high levels are found to be causative for androgen dependent disease like benign prostatic hyperplasia. Thus, 5α-reductase has been recognised as an important target for discovering new drugs against Benign Prostatic Hyperplasia and Prostate Cancer. Methods: In the present study, a series of 5α, 6β-Dichloro-17-Oxoandrostan-3β-yl esters (7a-7f) were synthesized and characterized by analytical and spectroscopic methods. The compounds were evaluated for their 5α-reductase inhibitory activity in-vivo by their effect on serum androgen level. Results: The target compounds (7a-7f) showed increased anti-androgenic activity as compared to finasteride and control, which implies that the target compounds are effective in inhibiting 5α-reductase. Particularly, compound 7b showing highest inhibitory activity and noteworthy D-Score was further sorted by performing solubility and dissolution studies. Results of these studies when compared with finasteride showed increased solubility and dissolution of target compound 7b. Conclusion: These results demonstrated that enhancement of activity by the presence of electronegative group at position 3 of the steroidal nucleus makes 7b a lead compound for further exploration and optimal formulation.
科研通智能强力驱动
Strongly Powered by AbleSci AI